Rejected from Journal of Experimental and Clinical Cancer Research? Where to Submit Next

The useful question is not "which oncology journal is easier?" It is "what did JECCR not believe about this manuscript?"

If the editor did not believe the translational bridge, the next journal should probably be either more basic, more clinical, or more disease-specific. If reviewers believed the cancer question mattered but the mechanism was thin, the manuscript needs repair before resubmission. If reviewers questioned model relevance, patient cohort strength, assay validation, statistical control, animal design, biomarker actionability, data availability, or declarations, those problems travel with the paper.

Use the decision letter to classify the failure:

JECCR is not simply a general oncology journal with broad scope. The source-backed fit screen is bench-to-bedside. A manuscript can be technically correct and still fail if it does not connect laboratory evidence to a credible cancer understanding, prevention, diagnosis, treatment, or clinical interpretation.

That makes the rejection diagnostically useful. It often means one of three things:

• The biology is cancer-related but not translational enough. A pathway, gene, model, assay, or phenotype may be interesting, but the patient or disease consequence is still implied.
• The clinical association is useful but not experimental enough. A cohort, prognostic model, or biomarker paper may matter clinically, but JECCR may expect stronger mechanism, validation, or bench-to-bedside logic.
• The evidence package is not aligned. The manuscript may combine cell lines, animal models, patient samples, omics, and treatment claims, but the pieces do not support one proportional conclusion.

This is why the next submission should be routed by manuscript phenotype, not by impact-factor adjacency.

This page was researched from the current Springer Nature and BMC JECCR journal pages, aims and scope, submission guidelines, editorial board, fees-and-funding page, existing Manusights JECCR pages, and adjacent oncology journal positioning. The official materials consistently frame JECCR around cancer research from bench to bedside and a translational bridge from laboratory findings to understanding, prevention, diagnosis, or treatment.

In our analysis of the post-rejection routing job, the non-obvious question is not whether Molecular Cancer or Cancer Letters is "next." It is which manuscript component created the rejection signal: disease model, patient cohort, mechanistic experiment, biomarker validation, drug-response evidence, statistical adjustment, figure order, declarations, data availability, cover letter, or limitations.

The specific rejection patterns below are written as a diagnostic, not as a generic journal list. We see authors lose time when they interpret a JECCR rejection as a prestige problem, but the paper actually has a translation, mechanism, or evidence-alignment problem. In practice, the best next journal is the one where the manuscript's evidence can support its claim without forcing a bench-to-bedside story that the data cannot carry.

Rebuild for JECCR only when the manuscript still has a credible bench-to-bedside cancer claim and the rejection exposed a repairable weakness. This is most plausible after a detailed review, a revision decision, or a desk rejection where the science was relevant but the translation or package discipline was not obvious enough.

Good reasons to rebuild:

• The paper links cancer mechanism to diagnosis, prognosis, prevention, therapy, resistance, patient stratification, or disease understanding in a way the current draft hid.
• The rejection letter questioned framing, model relevance, reporting completeness, declarations, data availability, or fit argument rather than the core study.
• The missing validation, control, cohort stratification, dose-response, rescue experiment, animal endpoint, or figure-order correction is achievable.
• The strongest translational consequence was buried in the discussion instead of visible in the title, abstract, first figure, and cover letter.

Bad reasons to rebuild:

• You only want to stay near a double-digit impact-factor oncology venue.
• The paper is interesting cancer biology but has no credible clinical line of sight.
• The paper is clinically relevant but mechanistically thin.
• The key limitation requires a new cohort, new animal study, new drug-response series, or different experimental design.

If you rebuild, make the correction visible early. A new cover letter cannot rescue a manuscript whose title, abstract, and first figure still read like the wrong journal.

Molecular Cancer can be a better next route when the paper's strength is a broad molecular oncology claim. If the main contribution is a cancer mechanism, pathway, regulatory network, tumor microenvironment interaction, therapeutic resistance mechanism, or multi-omics insight, the next editor needs to see molecular consequence first.

Cancer Letters can fit studies that are rigorous and cancer-facing but not quite broad, definitive, or translationally complete enough for JECCR. It can be a good home for manuscripts where the result is useful but the clinical bridge should be written more modestly.

Oncogene can be better when the manuscript's center is oncogenic signaling, tumor suppressor biology, cancer progression, resistance, or mechanistic tumor biology. It is often more coherent than forcing a broad translational story if the best evidence is mechanistic.

Choose these routes when the manuscript can answer:

• What cancer process does the result explain better than before?
• Which mechanism, model, patient evidence, or intervention supports that explanation?
• Is the clinical claim demonstrated, or only suggested?
• Does the paper need a broad translational oncology audience, or a mechanistic oncology audience?

If the answer is mostly "the marker correlates with outcome," repair the validation and interpretation before retargeting.

Many JECCR rejections are good papers in the wrong lane.

Move toward Clinical Cancer Research or another clinical-translational venue when the manuscript's value is treatment selection, therapeutic resistance, diagnostic performance, prognostic use, trial implication, patient stratification, or clinical decision-making. The rewrite should make actionability and limitations explicit rather than using broad mechanistic language.

Move toward a cancer-type specialist journal when the work is strongest for lung cancer, breast cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, glioma, melanoma, hematologic malignancy, pediatric oncology, gynecologic oncology, or another defined disease community. The rewrite should speak to that audience's model systems, endpoints, treatment context, and reviewer expectations.

Move toward methods, pathology, genomics, immunology, pharmacology, or biomarker journals when the strongest contribution is technical. A classifier is not automatically a clinical tool. An expression signature is not automatically a mechanism. A drug screen is not automatically a therapeutic claim. The next journal should match what the evidence actually proves.

In our pre-submission and post-decision review work with manuscripts aimed at Journal of Experimental and Clinical Cancer Research, the highest-value repairs are usually not language edits. They are routing and evidence-alignment decisions tied to concrete components: title, abstract, first figure, tumor model, patient cohort, mechanistic experiment, drug-response assay, biomarker validation, statistical adjustment, data-availability statement, declarations, cover letter, and limitations.

Three specific rejection patterns are especially common.

The translational-bridge gap. The manuscript contains cancer biology, but it does not prove why the biology matters from bench to bedside. The abstract names diagnosis, treatment, prognosis, resistance, or patient stratification, but the figure sequence mostly shows expression, proliferation, migration, or pathway association. JECCR is risky when the translational consequence appears only in the discussion. The repair is to make the clinical line of sight concrete: disease stage, treatment context, patient subgroup, endpoint, or mechanism-to-action path.

The mechanism-versus-marker gap. The manuscript treats a marker, signature, or expression change as if it were a mechanism. Reviewers may accept that a gene, protein, pathway, noncoding RNA, immune cell, or microbial feature associates with cancer behavior, but that is not the same as causal explanation. The repair is to separate discovery from mechanism and add the experiment, validation, or limitation language needed for the next venue.

The package-discipline gap. The science may be publishable, but the submission package looks fragile. Declarations, ethics approvals, data availability, cell-line authentication, animal methods, statistical plan, supplementary files, and figure legends must support the claim. When these pieces are scattered or incomplete, reviewers focus on trust before they reach novelty. The repair is to make the evidence auditable before asking another editor to invest reviewer time.

For JECCR specifically, we check whether the title, abstract, first figure, model choice, patient evidence, mechanistic experiment, and cover letter all make the same translational oncology promise. If the title promises treatment relevance but the data only support molecular association, the paper should either add evidence or move to a venue that values discovery. If the data support a specific cancer type rather than broad oncology, a specialist journal is often stronger than another broad translational target.

The practical lesson is direct: after JECCR rejection, the manuscript should either become a clearer bench-to-bedside oncology paper or a more honest paper for the audience that can use the evidence you actually have. The worst option is a cosmetic resubmission that preserves the same unsupported translational claim.